Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Current Assets (2022 - 2026)

Compass Therapeutics' Current Assets history spans 5 years, with the latest figure at $195.7 million for Q1 2026.

  • On a quarterly basis, Current Assets rose 57.63% to $195.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $195.7 million, a 57.63% increase, with the full-year FY2025 number at $209.8 million, up 58.05% from a year prior.
  • Current Assets hit $195.7 million in Q1 2026 for Compass Therapeutics, down from $209.8 million in the prior quarter.
  • Over the last five years, Current Assets for CMPX hit a ceiling of $221.1 million in Q3 2025 and a floor of $106.2 million in Q2 2025.
  • Historically, Current Assets has averaged $165.5 million across 5 years, with a median of $162.6 million in 2023.
  • The widest YoY moves for Current Assets: up 58.05% in 2025, down 30.84% in 2025.
  • Tracing CMPX's Current Assets over 5 years: stood at $194.8 million in 2022, then fell by 21.0% to $153.9 million in 2023, then fell by 13.73% to $132.8 million in 2024, then surged by 58.05% to $209.8 million in 2025, then dropped by 6.74% to $195.7 million in 2026.
  • Business Quant data shows Current Assets for CMPX at $195.7 million in Q1 2026, $209.8 million in Q4 2025, and $221.1 million in Q3 2025.